Importantly, early diagnosis and treatment of tumors can be optimized even when cancerous tissues are not available, measuring LOX-1 biomarker in liquid biopsy, as demonstrated in the serum of CRC patients. This evidence concerns the gene OLR1 and colorectal carcinoma.